Nosa Plugs Ab · OMXSTO:NOSA
Nosa Plugs Ab — NOSA — Investor Presentation (March 2023)
17 slides from Nosa Plugs Ab's investor presentation, Mar 1, 2023
Slide 1: Presentation 1 mars 2023
NOSA Breathe with care NY Presentation 1 mars 2023
Slide 2: The Better Breathing Company
THE BETTER BREATHING COMPANY
Slide 3: NOSA is a revolutionary nasal product technology for better breathing
NOSA is a revolutionary nasal product technology with a mission to create better breathing experiences Sales NOSA solves the problem of breathing unpleasant 8 000 000 and harmful airborne particles such as: • Odor, pollen, virus and bacteria 7 000 000 6 000 000 5 000 000 Founded in 2011 by nurse Sus
Slide 4: We reach and activate our customers through direct selling and sampling
We reach and activate our customers through direct selling and sampling with sales through distributors PRODUKTION DISTRIBUTION PRODUKTION SLUTKUND DISTRIBUTION SLUTKUND PRODUCTION SALES PRODUKTION DISTRIBUTION DISTRIBUTION CUSTOMER SLUTKUND - Produktutveckling - Sälj/Marknad - Produktutveckling - S
Slide 5: We are now transitioning into scale up phase
We are now transitioning into scale up phaze - New packaging partners in USA and Poland - Commercialization - Launch Benelux NOSA plugs - Automization of - Launch Nordics production i Sweden - Consumer package - Launch Germany - Launch NOSA - Production developed - Patent filed for NOSA microbial co
Slide 6: A strong product portfolio addressing large breathing related problems
A strong product portfolio that has been developed to address large breathing related problems 2017 2022 2020 Launch NOSA plugs Launch NOSA microbial Launch NOSA filter - Customers - Customers - Customer B2B: Healthcare, police B2B: Hospital, public transport B2C: Allergy sufferers B2C: Fragrance se
Slide 7: NOSA plugs – Effectively reduces bad smell
NOSA plugs – Effectively reduces bad smell and enabling a better working environment The world’s first discreet odor protection ü Reduces bad smell ü Easy to breathe through ü Discreet and comfortable Used in situations where bad odour occurs such as: wound care, incontinence, body odors or corpses.
Slide 8: NOSA microbial control – Fighting virus and bacteria
NOSA microbial control – Fighting virus and bacteria NOSA microbial control reduces virus and bacteria in the air we breathe A reduced exposure of viruses and bacteria reduces the risk of respiratory infections ü Reduces virus and bacteria ü Comfortable and discreet ü Easy to breathe through B2C – 7
Slide 9: NOSA filter – Nasal filter that enables breathing without allergic reactions
NOSA filter – Nasal filter that enable people to breathe without allergic reactions A discreet nasal filter that efficiently filters harmful airborne particles ü Easy to breathe through ü Seals tight ü High efficiency filter B2C – 7-pack NOSA allergy filter PM 10 • Pollen • Pet dander • Dust • Mold
Slide 10: Loyal and highly satisfied customers in both B2B and B2C
Loyal and highly satisfied customers in both B2B and B2C Listed in most major hospitals in Northern Europe: Primary target customers are nurses, caretakers and field police officers • Nordics: NOSA plugs is procured by • Germany: almost all regions in Sweden and Finland • Netherlands: 9/10 nurses wo
Slide 11: Strong IP portfolio and unique production technique
Strong IP portfolio and unique production technique Patent Patent & Trademark Patent • Granted patent on NOSA plugs and filter. • Based on design and function • Includes slow release of drugs • Patent pending on NOSA microbial control Hard to copy • Unique production technique • Know how Owns critic
Slide 12: Large addressable market with 15 BSEK potential in Europe alone
Large addressable market with 15 BSEK potential in Europe alone NOSA addressable market Supporting megatrends Includes major European countries and North America. - Increasing population - Ageing population 52.3 million health care workers (of wich 34.5 - Worsening air pollution - Increased healthca
Slide 13: Strong potential in a scalable business model based on two thrusts
Strong potential in a scalable business model based on two thrusts Thrust 1 Market penetration NOSA plugs today • High growth in current product portfolio • Sweden 2,7% of healthcare personnel • Strong margins, increasing over time • Generating 2,5 MSEK turnover • Loyal customers with high LTV • Lar
Slide 14: New products that could revolutionize treatment methods worldwide
New products that could revolutionalize treatment methods world wide NOSA olfactory training NOSA drug delivery Problem: 5% of global population experience a Problem: Traditional delivery mechanisms complete loss of smell (pre covid) of drugs has well known drawbacks. • Conventional treatment is ext
Slide 15: Proposed new members of the board
Proposed new members of the board Dan Josefsberg Tomas Ludvigsson Dan Mangell Chairman Board member Board member Long experience Founding partner at Founding partner from leading MedHouse, one of at NOSA and serial positions within Europes largest entrepreneur. Pwc, Mc Kinsey, recruitment Founder of
Slide 16: Key focus points post transaction with Frisq Holding
Key focus points post transaction with Frisq Holding Financial objectives Over all objective to drive significant top line growth • Significant capital increase post • Strengthen existing distributor network in key transaction enables further growth markets • Annual revenue growth of minimum 80% • E
Slide 17: Adrian Liljefors
Adrian Liljefors [email protected]